Renovascular hypertension: the role of angioplasty after selecting patients according to the doppler resistive index

Submission date	Recruitment status Stopped	Prospectively registered		
26/09/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
26/09/2005	Stopped Condition category	[X] Results		
Last Edited		☐ Individual participant data		
25/02/2009	Circulatory System	Record updated in last year		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Gilles Soulez

Contact details

CHUM-Notre-Dame
Département de Radiology
1560 rue Sherbrooke Est
Montréal
Canada
H2L 4M1
+1 514 890 8000 ext. 26522
gilles.soulez.chum@ssss.gouv.qc.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

The role of angioplasty after selecting patients according to the doppler resistive index: a randomised controlled trial

Study objectives

Medical treatment and renal angioplasty in renovascular hypertension

Ethics approval required

Old ethics approval format

Ethics approval(s)

Comite d'ethique de la recherche, Hopital Notre Dame, Centre Hospitalier de L'universite de Montreal (CHUM), Montreal, Québec approved on 14th May 2002.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Renovascular hypertension

Interventions

Added 25/02/2009: the study was terminated early due to recruitment issue.

Inclusion of patients presenting a controlled hypertension with 2 or 3 antihypertensive drugs and risk factors for renovascular hypertension. Selection on Doppler inclusion criteria (Resistive index less than 0.75) and renal angiography renal artery stenosis of more than 60% in diameter.

Group 1: Medical treatment (duration: 12 months)

Group 2: Renal angioplasty

Follow up for one year following angioplasty.

Trial details received: 12 Sept 2005

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Systolic and diastolic blood pressure 12 months post-randomisation

Secondary outcome measures

- 1. Blood pressure at 1 and 6 months post-randomisation
- 2. Clinical success on blood pressure control at 12 months
- 3. Serum creatine clearance when off antihypertensive drugs during 12 months? Does it mean that you have no control over those?
- 4. Morbidity related to cardiovascular events during follow-up
- 5. Incidence of renal artery restenosis

Overall study start date

01/09/2002

Completion date

30/03/2006

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

- 1. Hypertension greater than 140/90 mmHg with two hypertensive drugs
- 2. Hypertension less than 140/90 mmHg with three antihypertensive drugs
- 3. Aged greater than or equal to 30 years old, either sex
- 4. Atherosclerotic renal artery stenosis of more than 60% on catheter angiography or 70% on computed tomography (CT) or magnetic resonance (MR) angiography
- 5. Doppler resistive index less than 0.75

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

120

Key exclusion criteria

- 1. Creatinine clearance less than 30 ml/min
- 2. Non controlled hypertension (greater than 160/105 mmHg) despite 3 anti-hypertensive drugs
- 3. Renal artery stenosis greater than 95%
- 4. Fibromuscular dysplasia

Date of first enrolment

01/09/2002

Date of final enrolment

30/03/2006

Locations

Countries of recruitment

Canada

Study participating centre CHUM-Notre-Dame

Manhain L

Montréal Canada

H2L 4M1

Sponsor information

Organisation

Hospital Notre-Dame (Montréal) (Canada)

Sponsor details

1560 rue Sherbrooke Est Montréal Canada H2L 4M1

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/01w7qz648

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-52685)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	cost-benefit analysis results	01/03/2005		Yes	No